Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov 15;61 Suppl 5(Suppl 5):S434-41.
doi: 10.1093/cid/civ551.

Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014

Mamoudou H Djingarey  1 , Fabien V K Diomandé  2 , Rodrigue Barry  1 , Denis Kandolo  1 , Florence Shirehwa  3 , Clement Lingani  1 , Ryan T Novak  2 , Carol Tevi-Benissan  4 , William Perea  5 , Marie-Pierre Preziosi  6 , F Marc LaForce  7
Affiliations
Review

Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014

Mamoudou H Djingarey et al. Clin Infect Dis. .

Abstract

Background: A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African "meningitis belt" and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Faso, Mali, and Niger in December 2010 with great success. The remaining 23 meningitis belt countries wished to use this new vaccine.

Methods: With the help of African countries, WHO developed a prioritization scheme and used or adapted existing immunization guidelines to mount PsA-TT vaccination campaigns. Vaccine requirements were harmonized with the Serum Institute of India, Ltd.

Results: Burkina Faso was the first country to fully immunize its 1- to 29-year-old population in December 2010. Over the next 4 years, vaccine coverage was extended to 217 million Africans living in 15 meningitis belt countries.

Conclusions: The new group A meningococcal conjugate vaccine was well received, with country coverage rates ranging from 85% to 95%. The rollout proceeded smoothly because countries at highest risk were immunized first while attention was paid to geographic contiguity to maximize herd protection. Community participation was exemplary.

Keywords: Africa; PsA-TT; meningitis belt; meningococcal group A; rollout plan.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Group A meningococcal conjugate vaccine (PsA-TT) rollout (2010–2014) in countries of the African meningitis belt. Source: World Health Organization Inter-country Support Team report on PsA-TT campaigns (meningvax.org).
Figure 2.
Figure 2.
Annual and cumulative doses used in the group A meningococcal conjugate vaccine (PsA-TT) rollout from 2010 to 2014. Source: WHO Inter-country Support Team report on PsA-TT campaigns (meningvax.org).
Figure 3.
Figure 3.
Percentage of source of information about the campaign among persons interviewed after the group A meningococcal conjugate vaccine (PsA-TT) 2012 campaign in Ghana (structured interview during cluster sample survey). Other sources of information included friends, school, at the borehole, neighbor, community surveillance volunteer, and marketplace. Source: WHO Inter-country support team report (2012).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. LaForce FM, Kondé K, Viviani S, Préziosi MP. The Meningitis Vaccine Project. Vaccine 2007; 25(suppl 1):A97–100. - PubMed
    1. Sow SO, Okoko BJ, Diallo A et al. . Immunogenicity and safety of a meningococcal A conjugate vaccine in Africa. N Engl J Med 2011; 364:2293–304. - PubMed
    1. Kristiansen PA, Diomandé F, Ba AK et al. . Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd protection. Clin Infect Dis 2012; 56:354–63. - PubMed
    1. Daugla DM, Gami JP, Gamougam K et al. . Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet 2013; 383:40–7. - PMC - PubMed
    1. Novak RT, Kambou JL, Diomandé FV et al. . Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012; 12:757–64. - PMC - PubMed

MeSH terms